Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma

NCT04888611 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Glioblastoma

Interventions

BIOLOGICAL: Camrelizumab plus GSC-DCV
BIOLOGICAL: Camrelizumab plus Placebo

Sponsor

Huashan Hospital

Collaborators

[object Object]
[object Object]